Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Journey Medical Corporation before investing.

In this article, we go over a few key elements for understanding Journey Medical Corporation’s stock price such as:

• Journey Medical Corporation’s current stock price and volume
• Why Journey Medical Corporation’s stock price changed recently
• Upgrades and downgrades for DERM from analysts
• DERM’s stock price momentum as measured by its relative strength

About Journey Medical Corporation (DERM)

Before we jump into Journey Medical Corporation’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Want to learn more about Journey Medical Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Journey Medical Corporation.

Journey Medical Corporation’s Stock Price as of Market Close

As of March 24, 2025, 4:00 PM, CST, Journey Medical Corporation’s stock price was $6.540.

Journey Medical Corporation is up 13.94% from its previous closing price of $5.740.

During the last market session, Journey Medical Corporation’s stock traded between $5.730 and $6.600. Currently, there are approximately 20.54 million shares outstanding for Journey Medical Corporation.

Journey Medical Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Journey Medical Corporation Stock Price History

Journey Medical Corporation’s (DERM) price is currently up 16.16% so far this month.

During the month of March, Journey Medical Corporation’s stock price has reached a high of $6.600 and a low of $4.970.

Over the last year, Journey Medical Corporation has hit prices as high as $6.890 and as low as $2.850. Year to date, Journey Medical Corporation’s stock is up 67.26%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Journey Medical Corporation Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 21, 2025, there were analysts who downgraded Journey Medical Corporation’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Journey Medical Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Journey Medical Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Journey Medical Corporation’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Journey Medical Corporation (DERM) by visiting AAII Stock Evaluator.

Relative Price Strength of Journey Medical Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 21, 2025, Journey Medical Corporation has a weighted four-quarter relative price strength of 13.66%, which translates to a Momentum Score of 89 and is considered to be Very Strong.

Want to learn more about how Journey Medical Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Journey Medical Corporation Stock Price: Bottom Line

As of March 24, 2025, Journey Medical Corporation’s stock price is $6.540, which is up 13.94% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Journey Medical Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.